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Abstract The term chymase is used to signify a chymotrypsin-
like protease stored within the secretory granules of mast cells.
Primarily based on amino acid sequence homology, 18 chymases
have been identified among different animals. This study, which
compares the structure of the primary specificity pocket (S1
subsite), defines a subgroup of four chymases likely to have a
substrate specificity with more elastase- than chymotrypsin-like
qualities. This difference is due, primarily, to finding a Val
instead of a Gly at residue 199, a position corresponding to
Gly216 in bovine chymotrypsin and Val216 in neutrophil and
porcine elastases. Chymases with Val at 199 are found only in
animals expressing multiple chymases, consistent with the
premise that their substrate specificity differs from that of
chymases with Gly at 199. ß 2002 Published by Elsevier Sci-
ence B.V. on behalf of the Federation of European Biochemical
Societies.
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1. Introduction
The term chymase was intended to signify the presence of a
chymotrypsin-like serine protease in mast cells [1]. Primarily
based on sequence homology and immunological localization,
18 chymases have been identi¢ed forming a unique sub-family
of serine proteases [2,3]. Despite the number [3^10] only a few
chymases have been isolated and characterized biochemically.
Hydrolytic studies characterizing the substrate speci¢cities of
human, rat 1 (rat mast cell protease (RMCP)-1), rat 2
(RMCP-2), and dog chymases demonstrate a preference for
aromatic residues at the P1 position of substrates, consistent
with a chymotrypsin-like speci¢city [11^14]. Like human chy-
mase (HC), mouse mast cell protease 4 (MMCP-4), hamster
chymase 1, and the newly discovered rat vascular chymase,
have been shown to be e⁄cient converters of angiotensin I to
II [7,10,15], implying their chymotrypsin-like speci¢city.
Using standard nomenclature [16], the P1 residue of a pep-
tide/protein substrate forms part of the scissile bond (P1^P1’
bond) and interacts with the S1 subsite of the protease. In the
case of chymotrypsin/trypsin family proteases, the S1^P1 in-
teraction typically de¢nes the general speci¢city of the pro-
tease; that is, whether the protease exhibits chymotrypsin-,
trypsin- elastase- or aspase-like activity [17^22]. The crystal
structure of recombinant human chymase (rHC) bound to
the peptide inhibitor succinyl (Suc)AAPF-chloromethylketone
(CMK) de¢ned the S1^S4 subsite structure of this protease
[23]. The S1 subsite appeared as a deep slot-like cleft with a
mostly hydrophobic interior that could readily accommodate
an aromatic sidechain. Consistent with proteases closely re-
lated to chymotrypsin, the S1 subsite of HC was formed by
three sequence segments: 176^182, 196^203, and 206^209 [23].
Based on alignment to bovine chymotrypsinogen, these resi-
dues correspond to 189^195, 213^220, 225^228 [23]. Focusing
on the identity of the key residues forming the S1 subsite of
all chymases, we de¢ne a distinct subgroup likely to have a
substrate speci¢city di¡erent from that expected for a chy-
mase. The amino acid di¡erences distinguishing this subgroup
suggest a change towards an elastase-like speci¢city. This is
supported by characterization of rHC mutated to resemble
this subset.
2. Materials and methods
2.1. Materials
Substrates were from Bachem (Philadelphia, PA, USA) and bu¡ers
were from Calbiochem (La Jolla, CA, USA). Gelcode Blue was from
Pierce (Rockford, IL, USA).
2.2. Recombinant proteases and inhibitors
Variants rHC-G216V and rHC-S189N (G199V and S176N by the
sequence of HC) were produced by mutation of rHC previously char-
acterized [23]. The mutations were introduced by the overlap exten-
sion PCR method [24] and the nucleotide sequences of the mutated
chymases were con¢rmed by DNA sequence analysis. Similar to that
previously described for rHC [25], variants were expressed as the
three-part pseudo-zymogen fusion protein, N-ubiquitin-enterokinase
cleavage site-chymase-C, in a baculovirus^insect cell system. Activa-
tion by enterokinase and puri¢cation of each variant was similar to
that previously described for rHC [25]. Puri¢ed variant concentrations
were estimated from A280 nm where O280 nm HC = 24 500 M31 cm31.
This value was calculated based upon three Trp, nine Tyr, and three
cystine per HC molecule [26].
Serpins r(antichymotrypsin)ACT-L358 and rACT-L358W were pro-
duced in Escherichia coli and puri¢ed as previously described [27]. The
concentration of rACT was determined by titration with standardized
bovine chymotrypsin and the concentration of rACT-L358W was de-
termined by titration at pH 5.5 with standardized rHC [28]. Titrations
were performed in a solution of 1.0 M NaCl, containing either 0.1 M
Tris pH 8.0, or 0.1 M MES, pH 5.5.
2.3. Biochemical methods
Hydrolysis of peptide-nitroanilide (NA) substrates was followed
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continuously (readings taken at 1-s or 10-s intervals) by measurement
of A410 nm using a Beckman DU640 spectrophotometer. Kinetic pa-
rameters were determined from initial velocity vs. substrate concen-
tration plots, assuming O410 nm NA = 8800 M31 s31. Assay conditions
were 1.0 M NaCl, 0.1 M Tris^HCl pH 8.0, 9% Me2SO, 25‡C. Initial
velocities were determined over a 3-min assay period for rHC-S189N,
and over a 30-min assay period for rHC-G216V. Enzyme concentra-
tions in both cases were such that substrate consumption did not
exceed 5% of total, and plots of product accumulation vs. time were
linear. Data were analyzed using the curve ¢tting programs of Igor
Pro from Wavemetrics. Reactions of rHC with serpins were per-
formed in a solution of 1.0 M NaCl, 0.1 M Tris pH 8.0, 25‡C. Res-
olution of reactant/products of chymase^serpin reactions by SDS^
PAGE was performed using the gel compositions of Laemmli [29];
the separating gel consisted of 12% acrylamide/1% bis-acrylamide.
Protein bands were visualized by staining with Gelcode Blue.
2.4. Computer modeling
Swiss-pdbViewer from Glaxo-Wellcome was used to mutate the
rHC-peptide CMK crystal structure [23]; accession number 1PJP.
Potential steric clashes were evaluated over a range of rotomer struc-
tures according to the mutation program within the Swiss-pdbViewer
software.
3. Results
3.1. Structure of the S1 subsite among chymase family
members
The amino acid sequences of the residues forming the S1
subsite of 18 chymases are compared in Table 1. Chymotryp-
sinogen numbering assigned to crystallized HC [23] is used to
reference residues; this numbering system denotes structural
location and/or functional homologies among di¡erent mem-
bers of the chymotrypsin/trypsin family. Important positions
for determining the S1 subsite speci¢city of chymotrypsin-,
trypsin-, and aspase-like proteases are residues 189 and 226
at the bottom of the S1 pocket [17^22]. More important for
determining elastase-like speci¢city is position 216 located at
the mouth of S1 pocket. In elastases position 216 is usually a
Val residue while in other serine class proteases this position is
highly restricted to a Gly residue [17,30,31].
As shown in Tables 1 and 2, chymases exhibit a number of
di¡erent residues at positions 189. However, none are charged
residues found in trypsin- and aspase- like proteases. Exami-
nation of position 216 reveals that 4 of the 18 chymases have
Val instead of Gly at position 216 (Table 1, marked in bold
type). Further inspection ¢nds additional di¡erences highly
speci¢c for Val216 chymases (Table 2). All exhibit Asn, Val,
and Ala at residue positions 189, 190, and 213, respectively.
The constancy of this pattern suggests that Val216 chymases
de¢ne a speci¢c subgroup. The arrangement of Val190,
Ala213, and Val216 also is found in the S1 subsite of human
neutrophil elastase (Table 2).
Table 1
The primary structure of the S1 subsite of chymases
Chymasea Residues 189^195b 213^220 225^228
(176^182) (196^203) (206^209)
Human S-A-F-K-G-D-S V-S-Y-G-R-S-D-A P-A-V-F
Rat 1 S-A-Y-K-G-D-S V-S-Y-G-R-G-D-A P-A-V-F
Rat 2 A-A-F-M-G-D-S V-S-Y-G-H-P-D-A P-A-I-F
Rat 3 L-T-Y-K-G-D-S V-S-H-G-R-G-R-G P-I-I-F
Rat 4 L-A-Y-K-G-D-S V-S-H-G-P-D-R-G P-I-I-F
Rat 5 N-V-Y-K-G-D-S A-S-Y-V-H-P-N-A P-A-V-F
Rat VCH T-A-Y-T-G-D-S V-S-Y-G-H-P-D-S P-A-V-F
Baboon S-A-F-K-G-D-S V-S-Y-G-R-L-D-A P-A-V-F
Dog S-A-F-K-G-D-S V-S-Y-G-Q-N-D-A P-A-V-F
Mouse 1 T-A-Y-M-G-D-S V-S-Y-G-D-S-H-G P-A-V-F
Mouse 2 S-I-G-Q-G-D-S A-S-------S-Y-E P-A-V-F
Mouse 4 S-A-Y-K-G-D-S V-S-Y-G-R-G-D-A P-A-V-F
Mouse 5 N-V-Y-K-G-D-S A-S-Y-V-H-R-Q-A P-A-V-F
Mouse 9 S-V-Y-M-G-D-S V-S-S-G-R-G-N-A P-A-I-F
Hamster 1 S-A-Y-K-G-D-S V-S-Y-G-R-G-D-A P-A-V-F
Hamster 2 N-V-Y-K-G-D-S A-S-Y-V-L-R-N-A P-S-V-F
Gerbil 1 S-A-Y-K-G-D-S A-S-Y-G-R-G-D-A P-A-V-F
Gerbil 2 N-V-Y-K-G-D-S A-S-Y-V-R-R-N-A P-A-V-F
aHuman, baboon, dog, rat 1 and 2 chymases, and cathepsin G sequences are from Chandrasekharan et al. [3]. Rat 3^5 chymase sequences are
from Lu«tzelschwab et al. [9], and the rat vascular chymase sequence (VCH) is from Guo et al. [10]. The primary structure of rat chymase 5 is
identical to that termed rat chymase 3 by Ide et al. [42]. Mouse chymases 1, 2, 4, 5, and 9 sequences are from Sali et al. [4] and Hunt et al.
[6]. Hamster chymase 1 and 2 are from Shiota et al. [7] and Shiota et al. [8], and gerbil chymase sequences are from Itoh et al. [5].
bNumbers without parentheses are based on homology to chymotrypsin and numbers in parentheses are chymase sequence numbers.
Fig. 1. Hydrolysis of peptide-NA substrates by rHC-G216V. Activ-
ity is plotted as vA410 nm/(minUmM protease). In actual measure-
ments the rHC-G216V concentration was 1 WM. Product accumula-
tion to obtain activity was monitored for 30 min. Lines through
data were calculated using linear least squares analysis.
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3.2. Catalytic properties of rHC variants rHC-S189N and
rHC-G216V
To date a Val216 chymase has not been isolated. The ability
to express HC in recombinant form allows for mutation of its
S1 subsite to evaluate the role of speci¢c residues on substrate
hydrolysis. Given the distinctiveness of the residues found at
positions 189 and 216 of Val216 chymases, two rHC variants,
rHC-S189N and rHC-G216V, were produced and character-
ized. rHC-S189N demonstrated a substrate speci¢city similar
to that of native HC and rHC. That is, it hydrolyzed the
substrate SucAAPF-NA more e⁄ciently than SucAAPL-
NA. Values for kcat/KM, kcat and KM were 9.2U104 M31
s31, 55 s31 and 0.6 mM for SucAAPF-NA and 2U103 M31
s31, 3 s31, and 1.7 mM for SucAAPL-NA. The catalytic ac-
tivity of rHC-S189N was titratable by the chymase inhibitor,
rACT-L358W [28]. Similar to HC, the stoichiometry of inhi-
bition (SI) obtained for this measurement was near 1. The
stoichiometric titration of rHC-S189N activity by rACT-
L358W con¢rms the concentration of the protease estimated
from A280 nm.
In contrast, rHC-G216V demonstrated catalytic properties
unique for a chymase. As shown in Fig. 1, the variant at 1 WM
concentration did not catalyze the hydrolysis of the substrate
SucAAPF-NA measured by NA production at A410 nm. Under
the same assay conditions and 1 mM substrate, 4 nM HC
would produce a readily measurable hydrolytic rate of 0.10
vA410 nm/min. Also evaluated were four additional substrates
with di¡erent P1 residues. Catalytic activity was observed for
SucAAA-NA and SucAAPL-NA (Fig. 1), but not detected for
SucAAPV-NA and SucAAPM-NA (not shown). kcat/KM val-
ues for SucAAA-NA and SucAAPL-NA hydrolysis calculated
from the slopes of lines ¢t to the data in Fig. 1 were 1.4 M31
s31 and 1.2 M31 s31. The hydrolytic e⁄ciencies of both sub-
strates are uncharacteristically low for a true peptide-NA sub-
strate. kcat/KM values for the hydrolysis of SucAAA-NA by
neutrophil and porcine pancreatic elastases are 570 M31 s31
and 6300 M31 s31, respectively [32]. Proteinase 3, a second
elastase from human neutrophils, does not hydrolyze Su-
cAAA-NA, but does hydrolyze MeO-SucAAPV-NA exhibit-
ing a kcat/KM value of 3000 M31 s31 [33].
Computer modeling studies replacing residues Ser189 by
Asn and Gly216 by Val in the chymase^peptide CMK crystal
structure are supportive, in part, of the hydrolytic observa-
tions. The isopropyl sidechain of Val216 was found to project
Table 2
S1 subsite structure of V216 and G216 chymases and neutrophil elastase
aMost common residue at each position is reported in the top row of Gly216 and Val216 chymases.
bOf the Gly216 chymases, Val190 is only found in mouse chymase 9 and Ala213 is only found in gerbil chymase 1. The residues of mouse chy-
mase 2 were omitted due to the unusual structure of its S1 subsite which includes a three-residue deletion.
Fig. 2. SDS^PAGE analysis of rHC-G216V interaction with rACT-L358 (A, B) and rACT-L358W (C). Inhibitor concentration, [I]0, was varied
to achieve the reaction stoichiometries reported below lanes 3^5 in (A, B) and 3^6 in (C). The protease concentration, [E]0, was held constant
at 3.0 WM. [E]0 and [I]0 in control lanes was 3.0 WM (75 and 135 Wg/ml, respectively). Reactions were performed in a total volume of 25 Wl
and incubations were for 30 or 90 min at 25‡C. They were stopped by rapid freezing in liquid nitrogen. Immediately after thawing, reactions
were denatured by dilution to 60 Wl with hot SDS^DTT and further heating at 90‡C for 10 min. The entire sample was resolved by SDS^
PAGE. Letters on the right side of the gel signify the migration of the protease^serpin complex (C), intact inhibitor (I), cleaved inhibitor (H),
and free enzyme (E). Cleavage at the reactive site of rACTs results in fragmentation of the protein into two bands of size approximately 40
kDa and 4 kDa. The 4-kDa fragment is not resolvable on the separation gel used in these studies.
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into the S1 subsite and clash with the buried benzyl group of
the P1 phenylalanyl residue. Steric clashes with the buried
phenylalanyl residue were not observed with Asn at 189.
3.3. Characterization of the interaction of rHC-G216V with
serpins rACT-L358 (wild type-ACT) and rACT-L358W
To further evaluate the substrate speci¢city of rHC-G216V
and to eliminate the possibility of a contaminating protease in
small amounts, the inhibition of rHC-G216V with two serpins
was evaluated. Inhibition by serpins is typically re£ective of
the catalytic competence and the substrate speci¢city of a
protease. Serpins inhibit proteases by trapping them in a 1:1
covalent complex. The complex is a distorted form of the
serpin acyl^protease complex produced as the protease at-
tempts to hydrolyze the reactive site peptide bond (P1^P1’)
of the serpin [34]. The inhibition mechanism has been likened
to that of a suicide substrate [35]. Consistent with suicide
substrates, complex formation is not always 100% e⁄cient
and some cleaved serpin is found generated concurrent with
inhibition. Cleaved serpin is not inhibitory and its generation
results in SI values greater than 1 [14,36]. HC-serpin reactions
are an prime example of these reaction properties. Inhib-
ition by rACT-L358 and the reactive site variant rACT-
L358W demonstrate SI values of 4 and 1.5 and kinh
values of 2U104 M31 s31 and 2U105 M31 s31, respectively
[14].
As shown by SDS^PAGE in Fig. 2, the reaction of rHC-
G216V with both rACT-L358 and rACT-L358W results in the
production of a high molecular weight band (C) indicative of
the covalent protease^serpin complex. Analyses demonstrate
the time dependence of complex formation at di¡erent reac-
tion stoichiometries. The complete disappearance of the pro-
tease band (E) by 90 min in the rACT-L358 reaction con¢rms
that rHC-G216V is a catalytically competent protease and
that all the protease in the preparation was active. Complexes
were stable as demonstrated by a similar analysis of identical
reactions allowed to proceed for 18^72 h (not shown).
Cleaved inhibitor also was generated as demonstrated by the
appearance of a band (H) immediately below that of intact
inhibitor. The proportion of cleaved inhibitor to serpin^chy-
mase complex estimated from the relative intensities of the
bands suggests that the SI value for the reaction of rHC-
G216V with both serpins is between 1 and 2.
rACT titration of rHC-G216V hydrolytic activity is shown
in Fig. 3. The hydrolysis of both SucAAA-NA and SucAAPL-
NA was inhibited in a manner that required a near stoichio-
metric amount of inhibitor to enzyme. The SI value established
from the titration was between 1 and 2. An SI s 1 is consis-
tent with SDS^PAGE analyses of reactions (Fig. 2) showing
two reaction products: protease^inhibitor complex and some
cleaved inhibitor. These results demonstrate that the turnover
of both substrates is due to catalysis by rHC-G216V.
The reaction of rACT-G216V with rACT-L358 and rACT-
L358W is re£ective of an altered substrate speci¢city. Based
on the disappearance of the protease band in the gel analyses
shown in Fig. 2, rACT-L358 appears as a somewhat more
e⁄cient inhibitor of rHC-G216V than rACT-L358W. This
¢nding is consistent with a preference for LeusTrp at the
P1 position of rACT and is in contrast to that observed for
HC (see above). Inhibition of rACT-G216V by rACT-L358W
was extremely slow; no more than half complete by 30 min as
shown in Fig. 2. Assuming that the reaction conditions in Fig.
2 approximate second order conditions ([E] = [I] = 3 WM), in-
hibition of HC (kinh = 2U105 M31 s31) would have been half
complete by approximately 2.0 s.
4. Discussion
Based on the distinctiveness of residues forming S1 subsite,
a subgroup of chymases was identi¢ed that may exhibit a
substrate speci¢city di¡erent from that expected of proteases
classi¢ed as members of the chymase family [3^10]. Most dis-
tinctive was Val instead of Gly at position 216 and Asn in-
stead Ser at position 189 (Table 2). Residues at these positions
are known to in£uence the S1 subsite speci¢city of serine
proteases [17^22]. Characterization of two mutants of rHC,
one with Ser189 (176 chymase numbering) changed to Asn
and the other with Gly216 (199 chymase numbering) changed
to Val, demonstrated that a Val at position 216 could have a
marked e¡ect on substrate speci¢city. rHC-G216V did not
hydrolyze the common chymotrypsin/chymase substrate Suc-
AAPF-NA, but did hydrolyze peptide-NA substrates with Ala
and Leu residues at the P1 position. The tendency to hydro-
lyze substrates with Ala and Leu instead of Phe at the P1
position suggests that the substrate speci¢city of Val216
chymases may be more elastase-like than chymotrypsin-like
[11,17,30,32,33,37,38].
Val instead of Gly at position 216 is characteristic of hu-
man neutrophil elastase, proteinase 3 and porcine pancreatic
elastase [30,31]. In elastases, the isopropyl sidechain of Val216
functions to constrict the interior the S1 pocket [17,30], limit-
ing its speci¢city to relatively small aliphatic residues
[11,32,33,37,38]. The computer model of mouse chymase 5
(MMCP-5 obtained from the web site of A. Sali, http://tatia-
na.rockefeller.edu/), an example of a Val216 chymase, shows
the isopropyl sidechain of Val216 protruding into the S1
pocket opening, in a manner similar to elastases [4]. Modeling
of Val at position 216 in the chymase^peptide inhibitor crystal
structure also shows the isopropyl sidechain protruding into
the S1 pocket and clashing with the buried benzyl group of
the P1^Phe residue of the inhibitor. The catalytic properties of
Fig. 3. Titration of rHC-G216V hydrolytic activity by rACT. Reac-
tions containing 25 WM enzyme were incubated overnight at 25‡C
with increasing amounts of rACT. To assay for residual activity, re-
actions were diluted 10-fold with assay media containing 4.5 WM
SucAAA-NA or 3 WM SucAAPL-NA, and product accumulation
was monitored for 30 min. Residual activities were determined from
the rate of product accumulation and fractional activities were esti-
mated using the control activity (no inhibitor for incubation time)
as unity.
FEBS 25731 8-2-02
S. Solivan et al./FEBS Letters 512 (2002) 133^138136
rHC-G216V were not strictly elastase-like, however. rHC-
G216V did not hydrolyze peptide-NA substrates with Met
or Val at P1 and was inhibited, albeit at a slow rate, by an
rACT variant with a Trp residue at the P1 position.
HC is the ¢rst chymotrypsin-like protease to have Gly216
replaced by another residue. Three trypsin-like proteases have
been described with a residue other than Gly at the 216 posi-
tion: (1) A rat trypsin variant with Gly216 mutated to Ala
was produced to study the role of this substitution on sub-
strate speci¢city [39]; (2) a protein C variant with Gly mu-
tated to Ser was discovered as the underlying cause of a he-
molytic disorder [40]; and (3) a human tryptase isozyme,
termed K-tryptase, has Asp instead of Gly at position 216
[41]. Similar to that observed for rHC-G216V, characteriza-
tion of these trypsin-like proteases demonstrated greatly re-
duced or non-detectable catalytic activity for substrates hy-
drolyzed by their Gly216 counterparts.
The low catalytic e⁄ciency of rHC-G216V for model sub-
strates SucAAA-NA and SucAAPL-NA questions the capa-
bility of Va1216 chymases to function as e¡ective elastases.
rHC-G216V may not re£ect fully the catalytic potential of
Val216 chymases. Val216 chymases exhibit additional residue
changes in the S1 pocket that are highly conserved. These
changes, Ala190 to Val and Val213 to Ala, make the S1 pock-
et of Val216 chymases even more similar to neutrophil elas-
tase (Table 2). Although less likely, the current study does not
eliminate the possibility that amino acid di¡erences between
Gly216 and Val216 chymases away from the S1 pocket some-
how compensate for Val216, and that a true Val216 chymase
will demonstrate chymotrypsin-like speci¢city similar to
Gly216 chymases. To de¢ne the substrate speci¢city of
Val216 chymases with more certainty, a genuine member
of this subgroup needs to be isolated and studied biochemi-
cally.
At least four di¡erent animals, rats, mice, gerbils and ham-
sters, express a Val216 chymase (Table 1). Each animal ex-
pressing a Val216 chymase also expresses at least one
Gly216 chymase. Thus, the presence of a Val216 chymase ap-
pears to be in addition to a chymase with chymotrypsin-like
speci¢city. This observation is consistent with the premise that
Val216 and Gly216 chymases have di¡erent biological func-
tions. Phylogenetic trees developed from primary structure
comparisons have subdivided the chymase family into two
major groups termed K and L [3,15]. This division has been
related functionally to the ability of K chymases to convert
e⁄ciently angiotensin I to II [3]. Recent evidence disputes
the restriction of angiotensin conversion to K chymases
[10,15]. The current study further questions the functional sig-
ni¢cance of the K and L subgrouping as phylogenetic trees
show Val216 chymases within the K chymase subgroup
[3,15]. Val216 chymases likely would not be e⁄cient angioten-
sin converters because recognition of a P1^Phe is required.
Interestingly, Val216 chymases are placed as a subdivision or
branch within the K chymase subgroup, an observation per-
haps consistent the functional distinction of these chymases
proposed in this study.
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